Role of phosphate-binders in treatment of bone-mineral disturbances in chronic kidney disease with emphasis on phosphate homeostasis disorders in their development (review)


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

В статье обсуждаются нарушение обмена фосфатов и его последствия для больных хронической болезнью почек. Приведены весь спектр существующих фосфатбиндеров, их сравнительные характеристики и опыт применения в клинической практике.

Texto integral

Acesso é fechado

Sobre autores

N. Mikhailova

Bibliografia

  1. Schiavi S.C., Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int, 2004, 65:1—14.
  2. Dusso A.S., Brown A.I., Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289: F8-28.
  3. Berndt T, Kumar R. Phosphatonins and the regulationof phosphate homeostasis. Ann Rev Physiol. 2007; 69:341—359.
  4. Goetz R., Beenken A., Ibrahimi O.A. et al. Molecular insightsinto the Klothodependent, endocrine modeof action of FGF19 subfamily members. Mol Cell Biol. 2007;27:3417-3428.
  5. Kuro-o M., Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab. 2008; 19:239-245.
  6. Kuro-o M., Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens. 2006; 15:437-441.
  7. Shimada T., Kakitani M., Yamazaki I. et al. Targeted ablationof Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-568.
  8. Kurosu H., Ogawa Y., Miyoshi M. et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006, 281:6120-6123.
  9. Urakawa I., Yamazaki Y., Shimada T. et al. Klotho converts canonical FGF receptor into a speciphic receptorfor FGF23. Nature. 2006, 444:770- 74.
  10. Kuro-o M. Klotho and ageing. Biochim Biophys Acta, 2009, 1790:1049-58
  11. Ketteler M., Schlieper G., Floege J. Calcification and cardiovascular health: new insight into an old phenomenon. Hypertension. 2006;47:1027-1034.
  12. Giachelli C.M. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959-2964.
  13. Block G.A., Hulbert-Shearon T.E., Levin N.W. et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4): 607-617.
  14. Block G.A., Klassen P.S., Lazarus J.M. et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8): 2208-2218.
  15. Young E.W., Albert J.M., Satayathum S. et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-1187.
  16. Covic A., Kothawala P., Bernal M. et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. NDT 2009;24:1506-1523.
  17. Foley R.N., Collins A.J., Herzog C.A. et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20(2): 397-404.
  18. Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-28.
  19. Tonell M., Sacks F., Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627-2633.
  20. Sigrist M.K., Taal M.W., Bungay P., McIntyre C.W. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(6):1241-1248.
  21. Dhingra R., Sullivan L.M., Fox C.S. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879-885.
  22. Foley R.N., Collins A.J., Ishani A. et al. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:556-563.
  23. Foley R.N. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009;4(6):1136-1139.
  24. Foley R.N, Collins A.J., Herzog C.A. et al. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adult study. Kidney Blood Press Res. 2009;32:37-44.
  25. Tentory F, Blayney MJ, Albert JM. et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-530.
  26. Wills MR, Savory J. Aluminium poisoning: dialysis encephalopathy, osteomalacia and anemia. Lancet. 1983;2:29-34.
  27. Altmann P. Aluminium toxicity in dialysis patients: no evidence for a threshold serum aluminium concentration. NDT. 1993;8(Suppl. 1):525-34.
  28. Siem X. Uber die Wirkung des Aluminiums, unter besonderer Berucksichtigung der durch das Aluminium verursachten Lasionen in Zentralhervensistem. Naunyn Schmiedebergs Arch Pharmacol. 1897;40:58-120.
  29. Spaffarth J. Case of aluminium poisoning. Lancet. 1921:i:1301.
  30. Alfrey A.C., LeGendre G.R., Kaehny W.D. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N Engl J Med. 1976;294:184-88.
  31. Altmann P., Dhanesha U., Hamon C. et al. Disturbance of cerebral function by aluminium in hemodialysis patients without overt aluminium toxicity. Lancet. 1989;2:7-12.
  32. Damment S., Autissier V., Henderson R. Influence of Bile Acids on the Phosphate-Binding Efficacy of Lanthanum Carbonate and Sevelamer Hydrochloride. ASN Renal week 2007 abstracts SA-PO866.
  33. Zhang Q., Li M., Lu Y. et al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract. 2010;115(4):259-67.
  34. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
  35. Block G.A., Spiegel D.M., Ehrlich J. et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815-1824.
  36. Qunibi W., Moustafa M., Muenz L.R. et al. CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952-965.
  37. Barreto D.V., Barreto F. de C., de Carvalho A.B. et al. Phosphate binder impact on bone remodeling and coronary calcification - results of the BRiC study. Nephron Clin Pract. 2008;110:273-283.
  38. Lin H.-H, Huang C.-C. Comparison of 48-week treatment of sevelamer and calcium carbonate on serum fibroblast growth factor 23, klotho and fetuin-A in chronic hemodialysis patients: A randomized, open-label, parallel-group study. ISN Nexus Symposium Bone and the Kidney, Sept. 20-23, 2012, Copenhagen, Denmark, Abstract 100.
  39. Pennick M., Dennis K., Damment S.J.P. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharm. 2006, 46:738-346.
  40. Evans C.H. The occurrence and metabolism of lanthanides. In: Biochemistry of the Lanthanides. Plenum Press: New York, 1990, 285-337.
  41. Damment S.J.P, Greaves P., Downes N. The Toxicology of Lanthanum Carbonate (Fosrenol®), a New Non-Aluminum, Non-Calcium Phosphate Binder. ASN Renal week 2003 abstracts F-PO651.
  42. Hutchison A., Maes B., Vanwalleghem J. et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphataemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:8-19.
  43. Behets G.J., Dams G., Damment S.J.P. et al. Differencesin gastrointestinal calcium absorbtionafter ingestion of non calcium-containing phosphate binders. ISN Nexus Symposium Bone and the Kidney, Sept. 20-23, 2012, Copenhagen, Denmark, Abstract 98.
  44. Caravaca F.,· Santos I.,· Cubero J.J. et al. Calcium Acetate versus Calcium Carbonate as Phosphate Binders in Hemodialysis Patients. Nephron. 1992, 60:423-427.
  45. Emmett M. A comparison of calcium-based phosphorus binders for patients with chronic kidney disease. D&T. 2006;35:284-293.
  46. Whang R., Ryder K.W. Frequency of Hypomagnesemia and Hypermagnesemia Requested vs Routine. JAMA. 1990;263(22):3063-3064.
  47. Kikuchi K., Tanaka H., Gima M. et al. Abnormalities of Magnesium (Mg) Metabolism and Therapeutic Significance of Mg Administration in Patients with Metabolic Syndrome, Type 2 Diabetes, Heart Failure and Chronic Hemodialysis. Clin Calcium. 2012;22(8):1217-26.
  48. He K., Liu K., Daviglus M.L. et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation. 2006;113:1675-1682.
  49. Touyz RM. Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. Am J Physiol Heart Circ Physiol. 2008;294:H1103-H1118.
  50. Ishimura E.I., Okuno S., Yamakawa T. et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnesium Research. 2007;20(4):237-244.
  51. Ishimura E., Okuno S., Kitatani K. et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007;68:222-227.
  52. Salem S., Bruck H., Bahlmann F.H. et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol. 2012;35(1):31-39.
  53. Kircelli F., Peter M.E., Ok E.S. et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant. 2012;27:514-521.
  54. Peters F., Epple M. Simulating arterial wall calcification in vitro: biomimetic crystallization of calcium phosphates under controlled conditions. Z Kardiol 2001;90(Suppl. 3):81-85.
  55. De Francisco A.L.M., Leidig M., Covic A.C. et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) accessing efficacy and tolerability. NDT. 2010;25:3707-3717.
  56. Shobeiri N, Cruanes J, Curtis M. et al. Magnesium status is an underrecognized an potentially modifiable risk factor in CKD. ISN Nexus Symposium Bone and the Kidney, Sept. 20-23, 2012, Copenhagen, Denmark, Abstract 153.
  57. De Schutter T.M., Neven E., Behets G.J. et al. Effect of a magnesium-based phosphate binder on the development of media calcifications in a rat model of adenine-induced uremia. A comparative multiple dose study. ISN Nexus Symposium Bone and the Kidney, Sept. 20-23, 2012, Copenhagen, Denmark, Abstract 85.
  58. Russo D, Miranda I, Ruocco C. et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255-1261.
  59. Block G.A., Wheeler D.C., Persky M.S. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407-1415.
  60. Drüeke T.B., Massy Z.A. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol. 2012;23:1277-1280.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies